“…Third, specific subsets of Tregs, in particular those expressing activation markers such as CCR4, may exert more robust immunosuppressive functions, and hence be more closely associated with prognosis, than the entire population of Tregs [107]. Fourth, some oncogenic programs, such as those underlying (at least some instances of) lymphoma [108], head and neck cancer [109,110], gastric cancer [111] and colorectal carcinoma [112], involve a prominent pro-inflammatory component. In this setting, Treg-mediated immunosuppression may exert bona fide antitumor functions.…”